Reaction

Vascular Access Complication reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 799 reports · 35 co-occurring drugs

As of the last recalculation, Vascular Access Complication appears in 799 FAERS reports alongside 35 co-occurring drug terms. The strongest observed disproportionality signal is DICLOFENAC POTASSIUM, FILM COATED (PRR 89.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Diclofenac Potassium, Film Coated	28	89.8	90.1
Diclofenac Potassium Tablets	28	89.7	90.0
Diclofenac Potassium	28	69.9	70.1
Calcium Gluconate	29	65.0	65.2
Cortisone Acetate	28	61.2	61.3
Adalimumab-Fkjp	86	54.1	54.2
Adalimumab-Aaty	86	52.9	53.0
Adalimumab-Adaz	86	47.5	47.5
Sulfasalazine	109	41.9	41.9
Desoximetasone	25	35.3	35.3
Pegaspargase	16	34.7	34.8
Hydroxychloroquine Sulfate	96	31.1	31.1
Leflunomide	106	30.3	30.3
Tocilizumab	111	29.3	29.3
Infliximab	183	28.0	28.0
Pseudoephedrine Hydrochloride	10	25.7	25.7
Pseudoephedrine Hcl	10	23.9	24.0
Abatacept	109	23.6	23.6
Mercaptopurine	15	22.9	23.0
Pembrolizumab	83	22.8	22.8
Diclofenac Sodium 1%	28	21.1	21.1
Diclofenac Sodium Topical	28	21.1	21.1
Diclofenac Sodium Topical Gel, 1%	28	21.1	21.1
Cetirizine Hydrochloride Allergy	23	20.3	20.4
Cetirizine Hydrochloride Tablets	23	20.3	20.4
Epoetin Alfa	9	20.0	20.0
Adrenalinum	29	18.9	18.9
Leucovorin Calcium	13	18.0	18.0
Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose	4	12.8	12.8
Blinatumomab	5	12.6	12.6
Lenvatinib	15	12.1	12.1
Golimumab	38	12.1	12.1
Paricalcitol	6	11.1	11.1
Brentuximab Vedotin	4	10.2	10.2
Cinacalcet Hydrochloride	9	5.1	5.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.